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Background: Substance use disorder is a complex chronic disease that requires a multidisciplinary approach in 
treatment. Pharmacotherapy is one of the components in the treatment of this condition. This study sought to assess 
the accessibility of medicines used in the treatment of substance use disorders in both a public and a private health 
facility in Nairobi. 
Methodology: This descriptive cross-sectional study with both qualitative and quantitative components was carried 
out in April and May 2015 at two hospitals in Nairobi, Mathare Mental Hospital (public) and Chiromo Lane Medical 
Centre (private).  Data on availability and affordability was collected from the two sites and the WHO performance 
indicators for health facilities used to assess availability. Affordability was determined using the daily wage of the 
lowest paid government worker. Interviews with the key informants were conducted to determine factors that 
influence the accessibility of the medicines.  
Results: About 50% of medicines on the Kenya Essential Medicines List for management of substance use disorders 
were available in Mathare while Chiromo Lane had all of them. The mean stock out duration was 8 months and 0.5 
months in Mathare and Chiromo Lane, respectively.  More than 67 % of the medicines required less than a single day’s 
wage to buy a month’s supply in Mathare while in Chiromo Lane all the medicines required more than a single day’s 
wage to purchase.  The cheapest medicine required 0.3 days wage to purchase while the most expensive drug 
required 50 days wage to purchase.  
Conclusion: Medicines for the treatment of substance use disorders had limited availability but were relatively 
affordable in Mathare while their availability was better in Chiromo Lane but with limited affordability.  The Kenya 
Essential Medicines List for substance use disorders requires updating to include newer and more efficacious 
medicines. National guidelines for the treatment of substance use disorders should be developed and disseminated. 
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1. Introduction 
Drug addiction is compulsive drug seeking and using 
behaviour even in the face of terrible personal and 
social consequences. It is a brain disease that affects 
multiple brain circuits, including those involved in 
reward and motivation, learning and memory, and 
inhibitory control over behaviour. Addiction is 
preceded by dependence which is an adaptive state that 
occurs after repeated administration of a substance 
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leading to substance use disorder (SUD). It develops on 
the basis of an interaction between several factors that 
include pharmacological properties of the drug, 
vulnerability of the person and the environmental 
influence (Noeline, 2009). Patients with SUDs are 
usually regarded as social misfits or even criminals and 
do not receive the necessary treatment required and 
where available  it has been segregated from the rest of 
the general healthcare either geographically, financially 
or both (Mclellan et al, 2014). 
According to the global status report on alcohol and 
health 2014, approximately 5.1 % of the global burden 
of disease is due to alcohol use  which  is responsible for 
3.3 million deaths accounting  for 5.9% of all the deaths 
annually (World Health Organization, 2014).  The World 
drug report of 2010 estimated that about 5% of the 
world’s adult population had used an illicit drug at least 
once in that year about 27 million being problem users ( 
United Nations Office on Drugs and Crime, 2012).  
SUD is a common problem globally with extensive 
public health effects ranging from poor health 
outcomes, reduced economic productivity and 
insecurity among others (National Authority for the 
Campaign against Alcohol and Drug Abuse, 2012). 
Access to health care is a fundamental right of all 
citizens and is included in many international 
agreements and government policies. There are 
however factors that preclude attainment of this right. 
These  include unaffordable medicine prices, poor 
availability, irrational use of medicines, unfair health 
financing mechanisms and unreliable medicines supply 
systems (Kenya Service Provision Assessment Survey, 
2010). In Kenya, SUDs commonly reported are alcohol, 
nicotine, cannabis, opioid and psycho-stimulant use 
dependence.   
All substances of abuse are associated with poor health 
care service-seeking behaviours that  lead to worsening 
of other medical conditions not associated with the 
substance giving poor prognosis of many curable 
diseases among substance abuse patients (McCoy et al, 
2001).  
The treatment of substance abuse is multidimensional 
and may consist of biophysical, pharmacological, 
psychological and socio-cultural components. 
Pharmacological treatment is crucial as it enhances 
abstinence and prevents relapse, complementing 
psychosocial interventions that have been in use for 
many years. This is usually done at two levels involving 
detoxification and medication assisted treatment 
(MAT). Detoxification involves the treatment of 
withdrawal symptoms usually in patients with severe 
dependence (Fujii et al, 1974). 
There is substantial evidence supporting the role of 
pharmacotherapy in the management of substance 
abuse disorders (National Institute on Drug Abuse, 
2012). The type of pharmacotherapy employed varies 
depending on the substance of abuse. The new 
evidence-based modes of treatment are however not 
widely used in Kenya because protocols have not been 
disseminated and health care workers have not 
embraced them due to various factors.  
The main objective of this study was to carry out an 
assessment of the accessibility of pharmaceutical 
commodities used in the treatment of patients with 
substance use disorders in a public and a private 
hospital in Kenya. The specific objectives were to 
determine the availability and affordability of essential 
medicines used in the treatment of SUDs and factors 
that influence this. 
2. Methods 
2.1 Study design, site and population 
This was a cross-sectional study that was carried out in 
April and June 2015 at the drug rehabilitation units at 
Mathare Hospital and Chiromo Lane Medical Centre.  
These were the centres offering pharmacotherapy for 
SUDs in Nairobi at that time.  
2.2 Sampling Procedure 
The key informants were selected purposively from the 
two facilities and other locations such as the National 
Authority for the Campaign against Alcohol and Drug 
Abuse (NACADA) office, MOH office, retail chemists and 
private consultation clinics. 
2.3 Data Collection 
The availability and affordability of medicines for SUDs 
listed on Kenya Essential Medicines List (KEML) was 
assessed. The drugs were diazepam, methadone, 
clonidine, carbamazepine, thiamine and haloperidol.  
Other drugs not on the KEML but have been proven to 
be efficacious in evidence-based studies and are used 
routinely were also assessed. These drugs were: 
disulfiram, naltrexone, acamprosate, buprenophine, 
bupropion and nicotine replacement therapy (NRT). 
A data collection form was adapted from the Medicine 
Price Data Collection Form of the WHO/Health Action 
International manual and was used to collect data. 
Relevant inventory records on the medicines from the 
selected hospitals such as bin cards, stock cards, 
delivery notes and S11 books for the period January to 
December 2014 were also examined.   
Qualitative data was collected through 13 interviews 
were carried out with the hospital in-charges/medical 
superintendents, pharmacy in-charges, consultant 
psychiatrists, psychologists and community 
pharmacists as the key-informants. The interviews were 
tape-recorded and later transcribed.  
2.4 Data analysis 
The indicators on availability of the medicines were 
determined as a proportion/percentage. The total 
number of medicines that were available out of the total 
number of medicines under study gave the percentage 
availability. The number and percentage of expired 
medicines were also determined. The stock out period 
was taken as the number of days that the medicine was 
absent in the facility. The equivalent stock -out period 
was taken as the number of days the medicine was 
absent, multiplied by the number of days in a year and 
divided by the number of days covered by the study. 
Affordability was estimated as the number of days’ 
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wages of the lowest paid unskilled government worker 
needed to purchase medicines prescribed standard 
dose.  
The deductive approach was used in analysing 
qualitative data.  The transcribed data was read and 
research questions were used in grouping the data and 
looking for similarities and differences in the data 
collected. Codes were assigned to different themes. The 
themes identified were then organized into coherent 
categories that brought meaning to the text.  
2.5 Ethical consideration 
Ethical approval was obtained from ethics review 
committee by Kenyatta National Hospital and 
University of Nairobi (KNH/UON-ERC, Ref No.: 
P721/12/2014) before the study commenced. The 
researcher further sought permission from the 
management of the study sites before commencing data 
collection. 
 3. Results  
The availability and affordability of medicines on KEML 
list for SUDs was assessed. The drugs are diazepam, 
methadone, clonidine, carbamazepine, thiamine and 
haloperidol.  Other drugs not on the KEML but have 
been proven to be efficacious in evidence-based studies 
and are used routinely were also assessed. These drugs 
were: disulfiram, naltrexone, acamprosate, 
buprenophine, bupropion and nicotine replacement 
therapy (NRT). Availability of the medicines was 
assessed in the two facilities for the period from 
January 2014 to December 2014. Stock out was used to 
describe any drug that was not in stock at any time 
during the study period.  
In Mathare, diazepam and haloperidol (tablets and 
injections) were available but thiamine, clonidine and 
carbamazepine were out of stock.  Data on methadone 
was not accessed. About 50 % of medicines on the 
KEML that were available in Mathare while all 
medicines were available at Chiromo Lane but reported 
one expired medicine (Methadone) 
Disulfiram, naltrexone, acamprosate, buprenophine, 
bupropion and nicotine replacement therapy (NRT) 
were completely missing in Mathare. This is because the 
ordering for the medicines is usually done using the 
KEMSA standard order form which is adopted from the 
KEML. Medicines not on this list are usually not 
purchased except under special circumstances.  About 
72% of this category of medicine was available in 
Chiromo Lane. Acamprosate and buprenophin were not 
available as they are currently not registered by the 
regulator for use in Kenya.   
The presence of expired commodities was assessed and 
proportion of the expired medicines out of all the 
medicines assessed was reported. Expiries were 
present in Chiromo at 25% of the medicines not on 
KEML. The number of days the selected medicines were 
out of stock was recorded and the equivalent in a year 
was determined. The findings are summarized in 
Figure 1. 
 
   Figure 1: Percentage Stock out in a Year 
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  Figure 2: Number of Days’ Wages Required to Purchase Medicine 
In Mathare, 54% of the medicines were out of stock the 
whole year in. Of these, 23% were out of stock for 2 
months while 8% were out of stock for 6 months. The 
average stock out period for this facility was 8 months. 
In Chiromo Lane, only one drug was out of stock for 14 
days in the year, accounting for 7% of the drugs 
surveyed. The average stock out period for this facility 
was 0.5 months. The affordability of treatment was 
investigated and reported as shown in Figure 2. 
 
   Figure 3: Number of Times Medicines Were Purchased in the Year 
 
 More than 67% of the medicines required less than a 
single day’s wage to buy a month’s supply in Mathare. In 
Chiromo Lane all the medicines required more than a 
single day’s wage to purchase. Cheapest medicine in 
Mathare was diazepam tablets which required 0.3 days 
wage to purchase while the most expensive was 
thiamine, requiring 15 days wage to purchase. In 
Chiromo Lane, the cheapest medicine was diazepam 
injection which required 1.5 days of wage to purchase 
while the most expensive was naltrexone requiring 50 
days of wage to purchase. 
 In Mathare, it was not possible to stock the relatively 
more expensive medicines not on KEML even if 
evidence had shown them to be more effective.  This is 
because the money used for such is usually from the 
revolving fund or facility improvement fund (FIF) that 
requires replenishment of funds through patient 
purchases. Drugs that are not affordable are unlikely to 
be purchased and thus jeopardise the objectives of the 
scheme. 
The number of times medicines for the treatment of 
SUDs were purchased for the facilities was investigated 
and the findings are presented in Figure 3. 
In Mathare, drugs for SUD treatment were purchased in 
only four months throughout the year. Carbamazepine, 
a medicine is usually used in the management of alcohol 
withdrawal symptoms was purchased the highest 
number of times.  
Procurement in public hospitals like Mathare is usually 
done bi-monthly. This could explain the few number of 
times when medicines were purchased. The list of 
medicines purchased is dependent on availability of 
funds and medicines could be dropped from the list an 
observation that can be a hindrance to ensuring 
compliance with medication 
In Chiromo Lane, medicines were purchased all year 
round. Procurement was not fixed to particular times 
but was need-based. Patients received all required 
medicines as per the prescription ensuring patient 
compliance with treatment. 
The medicine purchased the highest number of times 
was thiamine in Chiromo lane compared to 
carbamazepine in Mathare. The finding that both 
carbamazepine and thiamine were the most purchased 
in both facilities could be an indication that there were 
more patients with alcohol use disorders compared to 
other substances. 
A total of 8 key informants were interviewed. They 
were drawn from various sectors including policy 
makers (MOH), academia (UON), Public health sector 
(Mathare Hospital, KNH), Private health sector 
(Chiromo Lane, private consultants) and NACADA. All 
the key informants interviewed reported that 
combination therapy was most effective. Both 
psychotherapy (for attitude change) and 
pharmacotherapy (for detoxification and management 
of withdrawal symptoms) have to be used in order to 
achieve treatment success and prevent relapses. 
However, some of the key informants were not aware of 
some of the medicines used in management of 
particular SUDs. 
Medicines are used at almost all the stages of 
management of SUDs. For instance, detoxification from 
alcohol, the following were reported to be used by the 
interviewees: thiamine, diazepam, and carbamazepine. 
For maintenance, medicines for managing craving such 
as naltrexone are used.  Antabuse® (disulfiram) was 
found to be very unpopular with the interviewees 
because of its side effects.  
With regard to guidelines/protocols used in 
management of SUDs, interviewees reported to be using 
different guidelines for the management of SUDs. Some 
were not aware of the availability of a Kenya National 
guideline or protocol. The following documents came up 
from the interviews as being used by various key 
informants; National treatment protocol for substance 
abuse disorders in Kenya, NIDA, BNF. Some 
practitioners did not use any and they managed each 
patient as per their symptoms.   
The National treatment protocol for substance use 
disorders in Kenya is available to only a few 
practitioners in hard copy. It is not yet available in soft 
copy and hence not widely accessible. It was prepared 
in partnership between MOH department of mental 
health and the United Nations Office on Drugs and 
Crime (UNODC) but and was biased towards the 
narcotic substances. 
The medicines on the KEML were regarded by the 
interviewees to be more readily available. They 
however noted that the list was inadequate and needed 
to be updated as some of the medicines had become 
obsolete. Availability varied across the public and 
private facilities. Interviewees who were affiliated to 
private facilities reported a higher rate of availability 
compared to those affiliated to the public facilities. The 
lack of medicines in the facilities contributes to delayed 
treatment and worsening of symptoms. Availability of 
medicines for various SUDs differed considerably. For 
instance an interviewee reported that their facility did 
not have any form of NRT. 
Most of the interviewees had knowledge of newer and 
more efficacious drugs which were not on the KEML 
although not readily available.  Generics were available 
for most of the medicines surveyed although for some 
medicines, only originator brands that are more 
expensive were available.  There are plans by NACADA 
to contract a manufacturer in India to produce generic 
naltrexone. This will increase its availability. The 
naltrexone will be used for “mass treatment ˮ of alcohol 
use disorders. 
The issue of lack of registration for use of efficacious 
medicine in Kenya as used in other Countries was of 
concern. Similarly, local regulations on the handling of 
opioids could be a hindrance to the availability of these 
medicines at lower levels of health care. For instance, 
methadone which is a synthetic opioid can only be 
available at facilities from level 4 upwards. 
The general opinion of the interviewees was that 
medicines for the treatment of SUDs were affordable 
with a few exceptions.  It was argued that if the patient 
is able to spend money on the substance of abuse on 
almost a daily basis, he should be in a position to afford 
the medicine and avert the adverse health outcomes 
associated with the use of the substance. This can only 
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be done if the health care worker manages to convince 
the patient of the benefits associated with abstaining 
from substance use. 
The lack of generics for some of the medicines has made 
the cost to be high and unaffordable to the lowest-paid 
government workers who make most of the payments 
for the medicines out of pocket (OOP). Considering that 
these are disorders that require long term management, 
this type of payments is not sustainable.  Local 
insurance companies do not cover the cost of SUD 
treatment with exception of a few international 
insurance companies. 
4.0 Discussion 
Results obtained in this study support the hypothesis 
that the essential medicines for substance use disorders 
are not readily available and may not be affordable 
especially in the public sector. This compares with other 
studies done in Kenya and in other countries on the 
availability and affordability of essential medicines 
(MOH, 2009). The availability of medicines on the KEML 
was fairly high in the private facility as compared to the 
availability in the public facility. This compares with the 
study on availability of essential medicines for non-
communicable diseases done in Sri-Lanka which 
showed an availability of 54 % in public facility and 
89% in private sector (Dabare et al, 2014).  
In Chiromo Lane, 7% of the drugs were out of stock for 
less than a month due to unavailability of the drugs in 
the market at the particular time. Otherwise stock-outs 
were rare and over a short mean period (0.5 months) as 
medicines were procured promptly as per the patients’ 
needs.  
There is need to update the essential medicines list to 
include newer and efficacious molecules arising from 
evidence based studies ( Lingford-Hughes et al, 2012). 
From the key informant interviews, availability was 
poor in public facilities due to lack of funds and also 
poor prioritizing.  Prolonged public procurement 
bureaucracy, lack of funds and poor estimation of 
quantities were named as some of the reasons for the 
long periods of stock-outs. These reasons were also 
found in other studies on the availability of essential 
medicines (Mendis et al, 2007). 
SUDs and mental health in general are not regarded 
with the seriousness they deserve and there is therefore 
low allocation of funds to this department. Availability 
is further affected by the fact that most of the medicines 
are imported.  
The low incidence of expired medicines at the study 
sites showed good commodity management by the 
personnel. Some of the medicines found to have expired 
in the facilities were donated close to their expiry date. 
This contravenes the guidelines to drug donations 
which advise against donation of drugs close to their 
expiry date. This can be achieved through better 
inventory control by the donor companies and the 
intermediaries and also communication with the 
recipient prior to donating the medicines (World Health 
Organization, 2011). 
Medicines in the Chiromo Lane were significantly more 
costly than those in Mathare. This finding is supported 
by the findings in the study done in 2009 on 
accessibility to essential medicines (MOH, 2009). 
Medicines that cost more than a day’s wage could be out 
of reach to many patients. There are patients who might 
not be in any form of employment and may not afford 
the medicines. About 50% of Kenyans live below 1.00 
US $ a day according to a study done by commonwealth 
in 2011. Citizens in this group are unlikely to afford the 
medicines (Kenya Economic Report, 2013).  
Accessibility of essential medicines for the treatment of 
non-communicable diseases is generally low in low-
income countries (Hogerzeil et al, 2013). However there 
has been tremendous progress in improving 
accessibility to other drugs such as antiretroviral drugs, 
which are more expensive to produce. Medicines for 
treatment of SUDs are mostly off-patent and therefore 
cheap to produce. Urgent measures should be taken to 
improve the availability and affordability of medicines 
for the treatment of SUDs. 
Limitations 
The study was successfully carried out as planned. 
However, there were some limitations which could 
affect the generalization of these results since the other 
rehabilitation centres or hospitals in Nairobi do not 
provide pharmacotherapy for substance use disorders, 
only two hospitals were included in the study. It is 
acknowledged that a larger sample size would be more 
precise and provide more information. 
5.0 Conclusion  
Most of the essential medicines for the treatment of 
SUDS were available at both study sites. In Mathare, 
representing public sector, the availability was low 
compared to Chiromo Lane (private facility).  The 
frequent stock-outs reported of essential medicines at 
Mathare, could affect the accessibility of the medicines 
by the poor who would not afford to buy them at 
private facilities. Medicines found to be efficacious for 
the treatment of SUDs but not on the KEML were 
completely absent at Mathare although they were 
present at Chiromo Lane. Most of the medicines in 
Mathare were affordable, costing less than a day’s wage 
with exception of a few which cost more than 30 days’ 
wage and are therefore out of reach for most of the 
patients. 
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